Pacira BioSciences, Inc. 8-K

What Happened
Pacira BioSciences, Inc. announced that on January 27, 2026 its Board increased in size from nine to ten directors and appointed Dr. Samit Hirawat as a Class III director, effective immediately. Dr. Hirawat was also appointed to the Board’s Science and Technology Committee. The company disclosed the appointment in an 8-K and issued a press release on January 28, 2026.

Key Details

• Board size increased from 9 to 10 directors; Dr. Samit Hirawat appointed effective January 27, 2026.
• Dr. Hirawat joined the Science and Technology Committee.
• He will receive Pacira’s standard non-employee director compensation.
• The Board concluded Dr. Hirawat is independent under Nasdaq rules; no related-party arrangements were reported.

Why It Matters
This is a governance update that adds scientific and technical expertise to Pacira’s board, which may support oversight of product development and R&D strategy. The filing does not report any executive departures or financial results, so there’s no immediate direct impact on revenue or quarterly earnings disclosed in this 8-K. Investors should view this as a board composition change aimed at strengthening governance and committee-level expertise.